Úlceras digitales en esclerosis sistémica

Herrick, 2009, Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis, Arthritis Rheum, 60, 878, 10.1002/art.24333 Van den Hoogen, 2013, Classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative, Ann Rheum Dis, 72, 1747, 10.1136/annrheumdis-2013-204424 Galluccio, 2017, Points to consider for skin ulcers in systemic sclerosis, Rheumatology (Oxford), 56, v67, 10.1093/rheumatology/kex200 Hughes, 2018, Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design, J Scleroderma Relat Disord, 3, 170, 10.1177/2397198318764796 Suliman, 2017, Defining skin ulcers in systemic sclerosis: systematic literature review and proposed World Scleroderma Foundation (WSF) definition, J Scleroderma Relat Disord, 2, 115, 10.5301/jsrd.5000236 Sharp, 2016, Differential diagnosis of critical digital ischemia in systemic sclerosis: Report of five cases and review of the literature, Semin Arthritis Rheum, 46, 209, 10.1016/j.semarthrit.2016.05.001 Asano, 2015, Vasculopathy in scleroderma, Semin Immunopathol, 37, 489, 10.1007/s00281-015-0505-5 Allanore, 2018, Review: defining a unified vascular phenotype in systemic sclerosis, Arthritis Rheumatol, 70, 162, 10.1002/art.40377 Matucci-Cerinic, 2017, The “myth” of loss of angiogenesis in systemic sclerosis: A pivotal early pathogenetic process or just a late unavoidable event?, Arthritis Res Ther, 19, 162, 10.1186/s13075-017-1370-5 Del Papa, 2018, The role of endothelial progenitors in the repair of vascular damage in systemic sclerosis, Front Immunol, 9, 1383, 10.3389/fimmu.2018.01383 Lescoat, 2018, Ulnar artery occlusion and severity markers of vasculopathy in systemic sclerosis: A multicenter cross-sectional study, Arthritis Rheumatol Hughes, 2018, Exploring the patient experience of digital ulcers in systemic sclerosis, Semin Arthritis Rheum Khimdas, 2011, Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry, Arthritis Care Res, 63, 142, 10.1002/acr.20336 Mihai, 2016, Digital ulcers predict a worse disease course in patients with systemic sclerosis, Ann Rheum Dis, 75, 681, 10.1136/annrheumdis-2014-205897 Elhai, 2016, A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study, Ann Rheum Dis, 75, 163, 10.1136/annrheumdis-2014-206386 Amanzi, 2010, Digital ulcers in scleroderma: Staging, characteristics and sub-setting through observation of 1,614 digital lesions, Rheumatology, 49, 1374, 10.1093/rheumatology/keq097 Denton, 2012, Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: Data from the DUO Registry, Ann Rheum Dis, 71, 718, 10.1136/annrheumdis-2011-200631 Steen, 2009, Digital ulcers: Overt vascular disease in systemic sclerosis, Rheumatology (Oxford), 48, iii19 Matucci-Cerinic, 2011, Bosentan treatment of digital ulcers related to systemic sclerosis: Results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial, Ann Rheum Dis, 70, 32, 10.1136/ard.2010.130658 Allanore, 2016, Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: A prospective, observational cohort, Ann Rheum Dis, 75, 1736, 10.1136/annrheumdis-2016-209481 Guillevin, 2013, Functional impairment of systemic scleroderma patients with digital ulcerations: Results from the DUO Registry, Clin Exp Rheumatol, 31, 71 Jaeger, 2018, Functional disability and its predictors in systemic sclerosis: A study from the DeSScipher project within the EUSTAR group, Rheumatology (Oxford), 57, 441, 10.1093/rheumatology/kex182 Mouthon, 2017, Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function, Semin Arthritis Rheum, 46, 759, 10.1016/j.semarthrit.2017.01.001 Jaeger, 2018, Brief report: Smoking in systemic sclerosis: a longitudinal European scleroderma trials and research group study, Arthritis Rheumatol, 70, 1829, 10.1002/art.40557 Harrison, 2002, Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis, Arthritis Rheum, 46, 3312, 10.1002/art.10685 Milburn, 1989, Treatment of scleroderma skin ulcers with a hydrocolloid membrane, J Am Acad Dermatol, 21, 200, 10.1016/S0190-9622(89)70161-4 Sato, 2018, Hyperbaric oxygen therapy for digital ulcers due to Raynaud's disease, Case Rep Plast Surg Hand Surg, 5, 72, 10.1080/23320885.2018.1525684 Mirasoglu, 2017, Hyperbaric oxygen therapy for chronic ulcers in systemic sclerosis – case series, Int J Dermatol, 56, 636, 10.1111/ijd.13570 Thompson, 2001, Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis, Arthritis Rheum, 44, 1841, 10.1002/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8 Rademaker, 1989, Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: A double blind randomised study, BMJ, 298, 561, 10.1136/bmj.298.6673.561 Gliddon, 2007, Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril, Arthritis Rheum, 56, 3837, 10.1002/art.22965 Dziadzio, 1999, Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial, Arthritis Rheum, 42, 2646, 10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T Wigley, 1994, Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study, Ann Intern Med, 120, 199, 10.7326/0003-4819-120-3-199402010-00004 Scorza, 2001, Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study, Clin Exp Rheumatol, 19, 503 Ingegnoli, 2018, Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus, Semin Arthritis Rheum Seibold, 2011, Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: A randomized, double-blind, placebo-controlled, multicenter study, Arthritis Rheumatol, 63, 2483 Denton, 2017, Efficacy and safety of selexipag in adults with Raynaud's phenomenon secondary to systemic sclerosis: A randomized, placebo-controlled, phase II study, Arthritis Rheumatol, 69, 2370, 10.1002/art.40242 Korn, 2004, Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist, Arthritis Rheum, 50, 3985, 10.1002/art.20676 Khanna, 2016, Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials, JAMA, 315, 1975, 10.1001/jama.2016.5258 Chung, 2014, Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcersin patients with systemic sclerosis: Results of a prospective pilot study, J Am Acad Dermatol, 71, 400, 10.1016/j.jaad.2014.04.028 Roustit, 2013, Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: Systematic review and meta-analysis of randomised trials, Ann Rheum Dis, 72, 1696, 10.1136/annrheumdis-2012-202836 Roustit, 2018, On-demand sildenafil as a treatment for Raynaud phenomenon: A series of n-of-1 trials, Ann Intern Med, 169, 694, 10.7326/M18-0517 Hachulla, 2016, Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: The placebo-controlled SEDUCE study, Ann Rheum Dis, 75, 1009, 10.1136/annrheumdis-2014-207001 Shenoy, 2010, Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: A double-blind randomized cross-over trial, Rheumatology (Oxford), 49, 2420, 10.1093/rheumatology/keq291 Moinzadeh, 2016, Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients, J Rheumatol, 43, 66, 10.3899/jrheum.150382 Omarjee, 2017, Improvement of peripheral artery disease with sildenafil and bosentan combined therapy in a patient with limited cutaneous systemic sclerosis: A case report, Medicine (Baltimore), 96, e6988, 10.1097/MD.0000000000006988 Ladak, 2016, A review of the effects of statins in systemic sclerosis, Semin Arthritis Rheum, 45, 698, 10.1016/j.semarthrit.2015.10.013 Tingey, 2013, Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis, Arthritis Care Res (Hoboken), 65, 1460, 10.1002/acr.22018 Numata, 2017, Successful treatment of continuous intra-arterial administration of prostaglandin E1, urokinase and heparin for intractable digital ulcers by upper extremity arterial occlusion in diffuse cutaneous systemic sclerosis patient, J Dermatol, 44, e254, 10.1111/1346-8138.13935 Motegi, 2018, Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary, J Dermatol, 45, 349, 10.1111/1346-8138.14140 Del Papa, 2019, Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study, Arthritis Res Ther, 21, 7, 10.1186/s13075-018-1792-8